Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravis

Michael G Benatar, Ted Burns, Chris Frost

Research output: Contribution to journalArticle

Abstract

This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: In view of the likely sequence in which the various diagnostic tests will be used in everyday clinical practice, we have organized this Cochrane review accordingly and our broad goals are to address three related questions. The primary objective of this review is to ascertain the accuracy of anti-AChR antibody testing for the diagnosis of myasthenia gravis (MG). 1) To determine the accuracy of (a) anti-MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG amongst patients who are seronegative for AChR antibodies. 2) To determine the accuracy of (a) MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG regardless of the anti-AChR antibody serological status. The rationale for the first secondary objective is that these diagnostic tests are most relevant clinically in the population of patients who are seronegative for AChR antibodies. Since we anticipate that many studies will not separately report the diagnostic accuracy of these other tests for seropositive and seronegative myasthenia, our final objective is to examine the accuracy of these other tests amongst all patients combined (irrespective of whether AChR antibodies titers are elevated or not). The hope is that these data will provide an approximation of the accuracy of other tests for the diagnosis of seronegative myasthenia in the event that we are correct and data to answer our first secondary objective are not available.

Original languageEnglish (US)
Article numberCD008904
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number11
DOIs
StatePublished - Nov 8 2016

Fingerprint

Myasthenia Gravis
Routine Diagnostic Tests
Pharmacology
Anti-Idiotypic Antibodies
Antibodies
Cholinesterase Inhibitors
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravis. / Benatar, Michael G; Burns, Ted; Frost, Chris.

In: Cochrane Database of Systematic Reviews, Vol. 2016, No. 11, CD008904, 08.11.2016.

Research output: Contribution to journalArticle

@article{04de3eab0f4a4c26b3462afe9c5cdd8d,
title = "Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravis",
abstract = "This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: In view of the likely sequence in which the various diagnostic tests will be used in everyday clinical practice, we have organized this Cochrane review accordingly and our broad goals are to address three related questions. The primary objective of this review is to ascertain the accuracy of anti-AChR antibody testing for the diagnosis of myasthenia gravis (MG). 1) To determine the accuracy of (a) anti-MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG amongst patients who are seronegative for AChR antibodies. 2) To determine the accuracy of (a) MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG regardless of the anti-AChR antibody serological status. The rationale for the first secondary objective is that these diagnostic tests are most relevant clinically in the population of patients who are seronegative for AChR antibodies. Since we anticipate that many studies will not separately report the diagnostic accuracy of these other tests for seropositive and seronegative myasthenia, our final objective is to examine the accuracy of these other tests amongst all patients combined (irrespective of whether AChR antibodies titers are elevated or not). The hope is that these data will provide an approximation of the accuracy of other tests for the diagnosis of seronegative myasthenia in the event that we are correct and data to answer our first secondary objective are not available.",
author = "Benatar, {Michael G} and Ted Burns and Chris Frost",
year = "2016",
month = "11",
day = "8",
doi = "10.1002/14651858.CD008904.pub2",
language = "English (US)",
volume = "2016",
journal = "The Cochrane database of systematic reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravis

AU - Benatar, Michael G

AU - Burns, Ted

AU - Frost, Chris

PY - 2016/11/8

Y1 - 2016/11/8

N2 - This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: In view of the likely sequence in which the various diagnostic tests will be used in everyday clinical practice, we have organized this Cochrane review accordingly and our broad goals are to address three related questions. The primary objective of this review is to ascertain the accuracy of anti-AChR antibody testing for the diagnosis of myasthenia gravis (MG). 1) To determine the accuracy of (a) anti-MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG amongst patients who are seronegative for AChR antibodies. 2) To determine the accuracy of (a) MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG regardless of the anti-AChR antibody serological status. The rationale for the first secondary objective is that these diagnostic tests are most relevant clinically in the population of patients who are seronegative for AChR antibodies. Since we anticipate that many studies will not separately report the diagnostic accuracy of these other tests for seropositive and seronegative myasthenia, our final objective is to examine the accuracy of these other tests amongst all patients combined (irrespective of whether AChR antibodies titers are elevated or not). The hope is that these data will provide an approximation of the accuracy of other tests for the diagnosis of seronegative myasthenia in the event that we are correct and data to answer our first secondary objective are not available.

AB - This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: In view of the likely sequence in which the various diagnostic tests will be used in everyday clinical practice, we have organized this Cochrane review accordingly and our broad goals are to address three related questions. The primary objective of this review is to ascertain the accuracy of anti-AChR antibody testing for the diagnosis of myasthenia gravis (MG). 1) To determine the accuracy of (a) anti-MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG amongst patients who are seronegative for AChR antibodies. 2) To determine the accuracy of (a) MuSK antibody serological testing; (b) cholinesterase inhibitor testing; (c) RNS; and (d) SFEMG for the diagnosis of MG regardless of the anti-AChR antibody serological status. The rationale for the first secondary objective is that these diagnostic tests are most relevant clinically in the population of patients who are seronegative for AChR antibodies. Since we anticipate that many studies will not separately report the diagnostic accuracy of these other tests for seropositive and seronegative myasthenia, our final objective is to examine the accuracy of these other tests amongst all patients combined (irrespective of whether AChR antibodies titers are elevated or not). The hope is that these data will provide an approximation of the accuracy of other tests for the diagnosis of seronegative myasthenia in the event that we are correct and data to answer our first secondary objective are not available.

UR - http://www.scopus.com/inward/record.url?scp=84998880872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998880872&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD008904.pub2

DO - 10.1002/14651858.CD008904.pub2

M3 - Article

VL - 2016

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

SN - 1361-6137

IS - 11

M1 - CD008904

ER -